The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators
Press Release

The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators

"For too long, legitimate cannabinoid medicine has been trapped between two federal systems that were never designed to work together," said Duane Boise, CEO of MMJ International Holdings. "The FDA encourages clinical research into cannabinoids, yet companies pursuing those trials have faced extraordinary obstacles obtaining the pharmaceutical-grade materials required to conduct them. If the United States is serious about developing cannabinoid medicines, the regulatory framework must support science rather than obstruct it."

Read More